CA 125 and its relation to cardiac function

American Heart Journal

Volumn 137, Issue 6, 1999, Pages 1044-1049

  Nägele, Herbert ^a   Bahlo, Marlies ^b   Klapdor, Rainer ^b   Schaeperkoetter, Dorothea ^b   Rödiger, Wilfried ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; NORADRENALIN; TUMOR MARKER;

ARTICLE; HEART FAILURE; HEART FUNCTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0342680170     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70360-1     Document Type: Article

References (16)

1. Fritsche HA. Serum tumor markers for patient monitoring: a case-oriented approach illustrated with carcinoembryonic antigen. Clin Chem 1993;39:2431-4.
2. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115(8):623-38.
3. Nägele H, Klapdor R, Bahlo M, et al. Malignancies after heart transplantation: possible role for "tumor marker screening," especially with CEA. Anticancer Res 1995;15(6A):2411-2.
4. Nägele H, Klapdor R, Bahlo M, et al. Determination of tumor markers after heart transplantation. In: Klapdor R, editor. Current tumor diagnosis: applications, clinical relevance, trend. Zuckschwerdt-Müchen, Germany: Verlag; .1994. p 861-5.
5. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
6. Raine AE, Erne P, Burgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986;315:533-7.
7. Kenemans P, Yedema CA, Bon GG, et al. CA 125 in gynecological pathology: a review. Eur J Obstet Gynecol Reprod Biol 1993;49:115-24.
8. Kokubo K, Inaba K, Takei H, et al. A case of catamenial pneumothorax with elevated level of serum CA 125. Kyobu Geka 1996;49(13):1127-9.
9. O'Riordan DK, Deery A, Dorman A, et al. Increased CA 125 in a patient with tuberculous peritonitis: case report and review of published works. Gut 1995;36:303-5.
10. Seo T, Ikeda Y, Onaka H, et al. Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 1993;57:489-94.
11. Buller RE, Vasilev S, DiSaia PJ. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s. Am J Obstet Gynecol 1996;174:1241-53.
12. Patel VS, Lim M, Massin EK, et al. Sudden cardiac death in cardiac transplant recipients. Circulation 1996;94(9 Suppl):II-273-7.
13. Lloyd KO, Yin BW, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as amucin-type molecule. Int J Cancer 1997;71:842-50.
14. MacGowan GA, Mann DL, Kormos RL, et al. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997;79:1128-31.
15. Kubonishi I, Bandobashi K, Murata N, et al. High serum levels of CA125 and interleukin-6 in a patient with Ki-1 lymphoma. Br J Haematol 1997;98:450-2.
16. Apel RL, Fernandes BJ. Malignant lymphoma presenting with an elevated serum CA-125 level. Pathol Lab Med 1995;119:373-6.